Millipore Sigma Vibrant Logo
Atención: Nos hemos mudado. Los productos Merck Millipore ya no pueden adquirirse en MerckMillipore.comMás información

AB9672 Anti-Tau phospho Serine 214 Antibody

This Anti-Tau phospho Serine 214 Antibody is validated for use in WB for the detection of Tau phospho Serine 214.

Anti-Tau phospho Serine 214 Antibody: Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.
Research Category: Neuroscience Research Sub-Category: Neurodegenerative Diseases Gene Symbol: MAPT, MTBT2, MAPTL, PHF-tau, tau, DDPAC, FTDP-17, MGC138549, MSTD, TAU, FLJ31424, MTBT1, PPND UniProt Number: P10636
AB9672
100 µL  
Purchase on Sigma-Aldrich

Ofertas especiales

Descripción

Replacement Information

Ofertas especiales

100% Performance Guaranteed

Tabla espec. clave

Species ReactivityKey ApplicationsHostFormatAntibody Type
HWBRbAffinity PurifiedPolyclonal Antibody
Description
Catalogue NumberAB9672
Brand Family Chemicon®
Trade Name
  • Chemicon
DescriptionAnti-Tau phospho Serine 214 Antibody
Background InformationTau is a neuronal microtubule-associated protein found predominantly on axons and functions to promote tubulin polymerization and stabilize microtubules. Tau, in its hyperphosphorylated form, is the major component of paired helical filaments (PHF), the building block of neurofibrillary lesions in Alzheimer's disease (AD) brain. Hyperphosphorylated Tau is also found in neurofibrillary lesions in a range of other central nervous system disorders. Hyperphosphorylation impairs the microtubule binding function of Tau, resulting in the destabilization of microtubules in AD brains, ultimately leading to the degeneration of the affected neurons. Numerous serine/threonine kinases, including GSK-3beta, protein kinase A (PKA), cyclin-dependent kinase 5 (cdk5) and casein kinase II (CK2), phosphorylate Tau. Serine 214 is phosphorylated by GSK-3beta in AD brain.
References
Product Information
FormatAffinity Purified
HS Code3002 15 90
PresentationAffinity purified immunoglobulin. Liquid in Dulbecco's PBS (without Mg2+ and Ca2+), pH 7.3, 50% glycerol with 1.0 mg/mL BSA and 0.05% sodium azide.
Quality LevelMQ100
Applications
ApplicationThis Anti-Tau phospho Serine 214 Antibody is validated for use in WB for the detection of Tau phospho Serine 214.
Key Applications
  • Western Blotting
Application NotesWestern blot: 1:1,000. Suggested blocking buffer is 5% BSA-TBST for one hour at room temperature. Suggested antibody dilution buffer is 1% BSA-TBST. Suggested antibody incubation time is 2 hours at room temperature.

Optimal working dilutions must be determined by the end user.
Biological Information
ImmunogenSynthetic peptide of amino acids surrounding the phosphoSerine 214 site of human Tau.
HostRabbit
SpecificityTau phosphoSerine 214. The antibody recognizes Tau pSerine 214 in samples of recombinant human Tau treated with GSK-3beta for 45 minutes. The reactivity of the antibody is blocked with the pSerine 214 peptide but not the non-phosphopeptide or a generic phosphoSerine-containing peptide.
Species Reactivity
  • Human
Antibody TypePolyclonal Antibody
Entrez Gene Number
Entrez Gene SummaryThis gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.
Gene Symbol
  • MAPT
  • MTBT2
  • MAPTL
  • PHF-tau
  • tau
  • DDPAC
  • FTDP-17
  • MGC138549
  • MSTD
  • TAU
  • FLJ31424
  • MTBT1
  • PPND
Modifications
  • Phosphorylation
UniProt Number
UniProt SummaryFUNCTION: SwissProt: P10636 # Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N- terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
SIZE: 758 amino acids; 78878 Da
SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity). Interacts with SQSTM1 when polyubiquitinated.
SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cell membrane. Note=Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.DEVELOPMENTAL STAGE: Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
DOMAIN: SwissProt: P10636 The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
PTM: Phosphorylation at serine and threonine residues in S-P or T- P motifs by proline-directed protein kinases (PDPK: CDC2, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K- X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser- 622, Ser-641 and Ser-673 in several isoforms during mitosis. & Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur. & Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
DISEASE: SwissProt: P10636 # In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). & Defects in MAPT are a cause of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP17) [MIM:600274, 172700]; also called frontotemporal dementia (FTD) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons. & Defects in MAPT are a cause of pallido-ponto-nigral degeneration (PPND) [MIM:168610]. The clinical features include ocular motility abnormalities, dystonia and urinary incontinence, besides progressive parkinsonism and dementia. & Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease. & Defects in MAPT are a cause of progressive supranuclear palsy (PSP) [MIM:601104, 260540]; also known as Steele-Richardson- Olszewski syndrome. PSP is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613. & Defects in MAPT may be a cause of hereditary dysphasic disinhibition dementia (HDDD) [MIM:607485]. HDDD is a frontotemporal dementia characterized by progressive cognitive deficits with memory loss and personality changes, severe dysphasic disturbances leading to mutism, and hyperphagia.
SIMILARITY: Contains 4 Tau/MAP repeats.
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsMaintain at -20°C in undiluted for up to 6 months after date of receipt. Avoid repeated freeze/thaw cycles. Do not store in a self defrosting freezer.
Packaging Information
Material Size100 µL
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Número de referencia GTIN
AB9672 04053252283079

Documentation

Anti-Tau phospho Serine 214 Antibody Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

Anti-Tau phospho Serine 214 Antibody Certificados de análisis

CargoNúmero de lote
RABBIT ANTI-Tau phosphoSerine 214 POLYCLONAL ANTIBODY - 2118041 2118041
RABBIT ANTI-Tau phosphoSerine 214 - 2503015 2503015
RABBIT ANTI-Tau phosphoSerine 214 - 3157519 3157519
RABBIT ANTI-Tau phosphoSerine 214 - 3217001 3217001
RABBIT ANTI-Tau phosphoSerine 214 - 3217775 3217775
RABBIT ANTI-Tau phosphoSerine 214 - 3275042 3275042
RABBIT ANTI-Tau phosphoSerine 214 - 3385738 3385738
RABBIT ANTI-Tau phosphoSerine 214 - 3767421 3767421
RABBIT ANTI-Tau phosphoSerine 214 - 3891798 3891798
RABBIT ANTI-Tau phosphoSerine 214 -2632593 2632593
Show more

Referencias bibliográficas

Visión general referenciasPub Med ID
The retinoic acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a model for Alzheimer's disease-like tau phosphorylation.
Jämsä, A., et al.
Biochem. Biophys. Res. Comm., 319:993-1000 (2004)  2004

15184080 15184080
Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease.
Augustinack, J.C., et al.
Acta Neuropathol., 103:26-35 (2002)  2002

11837744 11837744
Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease.
Liu, F., et al.
FEBS Lett., 512:101-106 (2002)  2002

11852060 11852060
Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.
Liu, F., et al.
FEBS Lett., 530(1-3):209-214 (2002)  2002

12387894 12387894
Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by protein phosphatase 2A and 5.
Liu, F., et al.
Neuroscience , 115(3):829-837 (2002)  2002

12435421 12435421
Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein.
Alonso, A.D., et al.
J. Biol. Chem., 276(41):37967-37973 (2001)  2001

11495914 11495914
cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease.
Jicha, G.A., et al.
J. Neurosci., 19(17):7486-7494 (1999)  1998

10460255 10460255

Newsletters / Publications

Title
Research Focus - Volume 2, 2013

Productos y aplicaciones relacionados

Familias de productos

Nervous System Markers

The nervous system coordinates the voluntary and involuntary actions of the individual and transmits signals between different parts of the body.
Más información >>

Tau Antibodies, Kits & Proteins

Millipore’s Tau antibodies demonstrates specificity against microtubule binding protein Tau. See below for related products for Tau, based on the expertise of Upstate & Chemicon.
Más información >>

Categorías

Life Science Research > Antibodies and Assays > Primary Antibodies